Coulon has more than 20 years of sales, marketing and business development experience within the pharmaceutical industry. Although his background includes a broad list of therapeutic specialities, his strength is in ocular drug development.
Coulon has previously worked at Ciba Vision (Novartis), Akorn, Mallinckrodt Pharmaceuticals, Stonebridge Pharma (GSK), Auriga Laboratories and CCG Partners.
PharmOptima appoints business development director
Ophthalmology specialist hires Rick Coulon
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![The future of science is built on networks, not laboratories]()
The future of science is built on networks, not laboratories
More often than not, life science innovation depends on decades of international collaboration, shared infrastructure and open exchange of data, Plamena Markova, Head of International Relations at the European Molecular Biology Laboratory (EMBL), tells Dr Kevin Robinson
Research & Development
![Parsortix CTC platform detects ADC targets in breast and ovarian cancer]()
Parsortix CTC platform detects ADC targets in breast and ovarian cancer
A new, peer-reviewed study has shown that CelLBxHealth’s Parsortix platform can detect ADC-relevant targets on circulating tumour cells, including TROP-2 on EpCAM-low cells in triple-negative breast cancer
Regulatory
![Advanced mass spectrometry technique breaks free from specialist hardware]()
Advanced mass spectrometry technique breaks free from specialist hardware
Researchers at the University of Warwick and spin-out company Verdel Instruments have successfully demonstrated two-dimensional mass spectrometry (2DMS) on a benchtop instrument, making this powerful technique practical and affordable for everyday laboratory use